Insulet Stock Goes On A Wild Journey Following Its Beat-And-Raise Quarter

Core Insights - Insulet reported earnings of $1.24 per share on $706.3 million in third-quarter sales, exceeding analyst expectations of $1.14 per share and $678.4 million in sales [1][2] - The company's Omnipod insulin pump sales grew significantly, with a 25.6% increase in the U.S. and a 46.5% increase internationally [1] - For the year, Insulet has guided revenue growth to 28% to 29%, an increase from the previous forecast of 24% to 27% [2] Financial Performance - In the same period last year, Insulet earned 90 cents per share with $544 million in sales, indicating substantial year-over-year growth [2] - Analysts project earnings of $4.67 per share and total sales of $2.63 billion for the year [2] Stock Market Activity - Insulet's stock advanced 4% to $327 in premarket trading, with a cup-with-handle base forming and a buy point at $335.26 [3] - The stock may face downward pressure at its 50-day moving average [3]